title: Suppressive effects of combination therapy with mizoribine and FK 506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation.
authors.affiliation: Department of Surgery, Saitama Medical School, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Ogawa
authors.forename: I
authors.initials: I
authors.lastname: Koyama
authors.forename: T
authors.initials: T
authors.lastname: Shibata
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: N
authors.initials: N
authors.lastname: Akimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Taguchi
authors.forename: N
authors.initials: N
authors.lastname: Shinozuka
authors.forename: R
authors.initials: R
authors.lastname: Omoto
mesh_terms: D000818:Animals; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control*; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006937:Hypercholesterolemia; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D011817:Rabbits; D012263:Ribonucleosides / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D002784:Cholesterol; D016559:Tacrolimus